RecruitingNCT05526443
Austrian Registry for Evaluation of Treatment Patterns and Outcome in Patients With Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
Sponsor
Medical University of Graz
Enrollment
1,500 participants
Start Date
Jan 13, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
To systematically collect and analyse real-world data on treatment patterns, clinical outcomes and toxicities among patients with advanced pancreatic ductal adenocarcinoma (PDAC) undergoing systematic treatment in Austria
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- years, female and male
- ECOG (Eastern Cooperative Oncology Group) Scale 0-2
- Diagnosis of histologically confirmed locally advanced inoperable and/or metastatic PDAC
- Patients undergoing palliative 1st line therapy with a platinum- or gemcitabine- based chemotherapy in case of previous (neo)adjuvant therapy also patients who receive nal-Irinotecan/5-FU/Leukovorin as palliative first line are eglible
- Signed informed consent for prospective patients, for retrospective cases no informed consent is required
Exclusion Criteria2
- Patients with locally advanced operable PDAC who do not receive palliative chemotherapy
- Patients with locally advanced borderline resectable PDAC who do not receive palliative chemotherapy
Interventions
DRUGall approved chemotherapeutic agents from second line
all approved chemotherapeutic agents from second line
Locations(12)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05526443
Related Trials
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
NCT056635158 locations
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
NCT046786483 locations
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
NCT0697316127 locations
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
NCT0624477126 locations
Resilience and Equity in Aging, Cancer, and Health (REACH)
NCT046742671 location